Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

AUSTIN, Texas, July 14, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology®, the official peer-reviewed journal of the American Academy of Neurology. The findings demonstrate that statistically significant and clinically meaningful improvements in upper-limb motor impairment and function, ability to perform activities of daily living, and quality of life were sustained for at least two years following completion of in-clinic Vivistim® Paired VNS™ Therapy. With its publication, this data now represents some of the most comprehensive longitudinal evidence to date for any intervention approved for chronic ischemic stroke recovery.

The two-year follow-up data, published in Neurology, reports outcomes from 49 participants in the VNS-REHAB pivotal trial, demonstrating a high responder rate and substantial improvements in impairment and function including:

• Clinically meaningful response on the Fugl-Meyer Assessment of Upper Extremity impairment (FMA-UE) and/or the Wolf Motor Function Test (WMFT) in 76% of participants
• Average improvement of +7.5 points from baseline on the FMA-UE, exceeding the minimum clinically important difference (MCID) of ≥6 points
• Average improvement of +0.63 from baseline on the WMFT, exceeding the MCID of ≥0.4 points

Importantly, these upper-limb motor improvements also translated into impactful real-world changes in the daily lives of stroke survivors. Participants demonstrated statistically significant and clinically meaningful improvements across multiple patient-reported measures of activity, participation, and quality of life, including:

• Ability to perform activities of daily living, such as bathing and dressing (Activities of Daily Living subscale of the Stroke Impact Scale; SIS-ADL)
• Perceived ease of performing daily activities with the affected hand and arm, such as carrying heavy objects or tying shoelaces (Hand subscale of the Stroke Impact Scale; SIS-Hand)
• Amount of use and quality of movement of the affected hand and arm when performing activities of daily living, such as brushing teeth or typing (Motor Activity Log; MAL)
• Overall stroke-specific quality of life, such as mood, self-care, social participation and family roles (Stroke-Specific Quality of Life Scale; SS-QOL)

The study also captures positive three-year outcomes from 16 participants, providing further supporting evidence that the benefits are durable and maintained long-term. Additionally, a subset of the 49 total participants experienced further improvement in scores between years one and two, suggesting that recovery may continue over time with ongoing self-directed Vivistim Therapy.

“What distinguishes Vivistim Therapy from conventional rehabilitation is the ability to actively drive neuroplasticity and enable lasting changes. These two-year outcomes reinforce that the benefits are sustained over a long period of time and, for many individuals, they can continue to accrue. For stroke survivors who have spent years living with impairments, these results open new possibilities for continued recovery, greater independence, improved function, and a better quality of life, even years after their stroke,” said Teresa Jacobson Kimberley, PT, Ph.D., FAPTA, FASNR, a lead researcher on the study and Director of the Brain Recovery Lab at the MGH Institute of Health Professions.

In addition to data from patients enrolled in the VNS-REHAB trial, clinicians have observed similar long-term results in some of their earliest commercially treated patients. Dr. Christopher Kellner, a cerebrovascular neurosurgeon and Director of the Cerebrovascular Center at the Mount Sinai Health System in New York City noted, “The two-year outcomes published in Neurology are consistent with what I am observing with my own patients since the launch of our Vivistim Program in 2023. Beyond the measurable improvements in upper-limb motor function, patient-reported gains in daily living and quality of life are particularly meaningful. The formal publication of these findings further validates the durability of our observed in-clinic results and, I believe, will help expand access to this technology for more stroke survivors who could benefit.”

Taken together, these findings add to a growing body of evidence that Vivistim Therapy delivers meaningful recovery and durable results across multiple dimensions and are reflective of Mobia Medical’s commitment to generating broad-based clinical evidence to support expanded adoption.

“Publication of these two-year outcomes in Neurology represents an important milestone in the continued development of our clinical evidence base for Vivistim Therapy. At the heart of the data are real people who are regaining function, independence, and quality of life, and that is what drives everything we do,” said Richard Foust, President and CEO of Mobia Medical. “We believe the consistency and durability of our clinical outcomes will continue to strengthen awareness and adoption of Vivistim Therapy by key stakeholders and advance our mission to expand access for the millions of chronic stroke survivors who deserve a better path forward.”

The VNS-REHAB trial was a multicenter, triple-blinded, sham-controlled randomized controlled trial (n=108 participants) evaluating the safety and efficacy of Vivistim Paired VNS Therapy in chronic ischemic stroke survivors with moderate to severe upper extremity impairment. The pivotal results were published in The Lancet and supported FDA Premarket Approval of the Vivistim System in 2021. One-year follow-up data, published in Stroke in 2025*,* confirmed improvements were maintained at 12 months and the two-year data, now published in Neurology, further extend these findings. No long-term serious adverse events related to the therapy or stimulation were reported through two years of follow-up.

To learn more about the Vivistim® Paired VNS™ System, visit Vivistim.com/about. Click here to review the safety information.

References

Kimberley, Theresa J., Vora, Isha, Cramer, Steven C., Wolf, Steven L., Dawson, Jesse. (2026). Two-Year Retention of Benefits after Paired Vagus Nerve Stimulation in Stroke: Follow-Up of the VNS-REHAB Randomized Clinical Trial. Neurology, 107:e218298. doi:10.1212/WNL.0000000000218298

About Mobia Medical, Inc.

Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.